(AGENPARL) - Roma, 17 Ottobre 2024 - (AGENPARL) – gio 17 ottobre 2024 7.00 AM CEST / 17-Oct-2024 / Hansa Biopharma AB (STO:HNSA)
Q3 2024 marks highest ever in-market quarterly sales performance and fourth
consecutive quarter of strong sales performance
Lund, Sweden, October 17, 2024, Hansa Biopharma today announced its interim
report for January-September and third quarter 2024 financial results.
Søren Tulstrup, President and CEO, Hansa Biopharma said, “The third quarter of
2024 marks the highest ever IDEFIRIX[®] sales performance to date, resulting in
four consecutive quarters of strong sales performance. The launch of IDEFIRIX in
Europe continues to advance with adoption in international organ allocation
systems and an increase in new and repeat utilization in leading transplant
clinics. Equally, we see strong momentum in our clinical development programs in
autoimmune, gene therapy and transplantation. Enrollment in the Phase 3 GOOD
-IDES-02 study in anti-GBM has reached 86%. In the Post Authorization Efficacy
and Safety (PAES) study in kidney transplant enrolment has reached 78%. Finally,
just after quarter end, we communicated positive results from the 12-month
analysis of NICE-01, demonstrating that HNSA-5487 can robustly and very rapidly
reduce IgG levels, has clear redosing potential, and a favorable safety and
tolerability profile. Initial clinical development will focus on neuromyelitis
optica (NMO), myelin oligodendrocyte glycoprotein antibody disease (MOGAD), and
myasthenia gravis (MG).”
Financial Performance
The Company recorded total revenue of 78.4 MSEK. Of this, 69.5 MSEK is
attributed to IDEFIRIX sales, marking the highest ever quarterly in-market
sales. This excludes the impact of a 29.7 MSEK provision related to potential
price adjustments from cumulative sales since the launch of IDEFIRIX in Europe
in 2020. Of the total provision only 4.9 MSEK was related to Q3 sales. Net of
the provision, Q3 2024 IDEFIRIX sales were 39.8 MSEK and total year to date
IDEFIRIX sales were 114.5 MSEK. Previously, the Company recorded a provision of
19.9 MSEK in Q2 2024. Of this, 2.0 MSEK was related to sales in Q2 2024. Of the
total provision taken in Q2 and Q3 2024, 42.7 MSEK relates to previous periods
since launch in 2020.
Pipeline Progress
Progress across the pipeline included the strong momentum in enrollment in the
Phase 3 GOOD-IDES-02 study in anti-GBM (86%), and in the Post Authorization
Efficacy and Safety (PAES) study in kidney transplantation (78%). Further
efficacy data from the 15-HMedIdes-09 Phase 2 trial in Guillain-Barré Syndrome
(GBS) is scheduled to read out by the end of 2024. The ConfIdeS trial continues
to progress following completed randomization in May and data from the study is
expected to provide the basis for a Biologics License Application (BLA) with the
US Food and Drug Administration (FDA) in the second half of 2025. On 7 October
2024, Hansa announced positive results from a 12-month follow up analysis from
the NICE-01 trial of HNSA-5487, assessing IgG recovery, immunogenicity and
redosing potential.
Financial Summary
[][]
MSEK, unless otherwise stated Q3 2024 Q3 2023 9M 2024 9M 2023
– unaudited
Provision[1] (29.7) – (49.6) –
SG&A expenses (75.8) (111.7) (255.3) (344.5)
R&D expenses (79.6) (95.6) (274.3) (303.1)
Loss from operations (116.9) (202.2) (463.7) (613.0)
Loss for the period (103.8) (250.7) (530.3) (707.3)
Net cash used in operations (148.8) (193.8) (527.1) (582.7)
Cash and short-term 553.5 908.2 553.5 908.2
investments
EPS before and after dilution (1.53) (4.78) (8.67) (13.49)
(SEK)
Number of outstanding shares 67,814,241 52,671,796 67,814,241 52,671,796
Weighted average number of 67,814,241 52,597,502 61,162,934 52,495,705
shares before and after
dilution
the period
[1] Product sales in the
third quarter 2024 totaled
69.5 MSEK. Sales were offset
by a provision totaling 29.7
MSEK for potential credits
associated with volume
discounts and rebates. Year
to date 2024 IDEFIRIX product
sales totaled 164.1 MSEK and
were offset by a provision
totaling 49.6 MSEK. Net of
the provision, year-to-date
2024 product sales totaled
114.5 MSEK.
Conference Call Details
Hansa Biopharma will host a telephone conference today Thursday, October 17,
2024, at 14:00 CET / 8:00 am ET.
The event will be hosted by Søren Tulstrup, President and CEO, Evan Ballantyne,
CFO, and Hitto Kaufmann, CR&DO. The call will include a review of the interim
results and a business and pipeline update. It will be held in English.
Slides used in the presentation will be live on the company website during the
call under Events &
Presentations (https://www.hansabiopharma.com/investors/presentations-events/)
and will also be made available online after the call.
To participate in the telephone conference, please use the dial-in details
provided below:
Participant Dial In (Toll Free): 1-877-270-2148
Participant International Dial In: 1-412-902-6510
*Please ask to be joined into the Hansa Biopharma call
Join the webcast here:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=ld2DsRXz (https:/
/eur03.safelinks.protection.outlook.com/?url=https%3A%2F%2Fevent.choruscall.com%2
Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dld2DsRXz&data=05%7C02%7Cstephanie.kenney
%40hansabiopharma.com%7C852c0c3f85dd478558e608dce310452e%7C2baeedcdecb6405a84aaec
DAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C4000%7C%7C%7C&sdata=adJc%2FF%
2Be00nYggiQr1Ln%2BdHyCTlxksuh3uceqL2cX60%3D&reserved=0)
For the full financial calendar and list of events in 2024 please visit
https://www.hansabiopharma.com/investors/calendar/
This is information that Hansa Biopharma AB is obliged to make public pursuant
to the Securities Markets Act.
— ENDS —
For more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and
IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All
rights reserved.
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2Rw4GwJqEAnTMmnzYVBqghdYJ6rJpzkXKvVp2eLbxAGUaYnQtsov5sBiDLkoojqeLPyQ9twgoAKykC7wnfBMs37xVwromGs7uqEPGEtgXyTNLD.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/2Rw4GwJqEAnTMmnzYVBqghdYJ6rJpzkXKvVp2eLbxAGUaYnQtsov5sBiDLkoojqeLPyQ9twgoAKykC7wnfBMs37xVwromGs7uqEPGEtgXyTNLD.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Iscritti informativa urgente del Governo in merito ai recenti episodi di allarmi bomba negli istituti scolastici e agli attacchi hacker nella grande distribuzione alimentare
- Covid, Girelli (Pd): chiesta informativa urgente a Schillaci, commissione non può essere tribunale. Lettera scienziati rivendica indipendenza dalla politica
- MANOVRA. SCARPA (PD): TOGLIE 185 MILIONI AD ACCOGLIENZA COMUNI, CON NOSTRI EMENDAMENTI RISORSE DA ALBANIA A SAI
- In Municipio i bambini della scuola dell’infanzia San Vincenzo de’ Paoli
- COMUNICATO STAMPA CONTROLLI NOTTURNI DEI CARABINIERI E DELLA POLIZIA MUNICIPALE DENUNCIATA UNA COMMERCIANTE .doc
- Ucraina, Sardone (Lega): “Lista proscrizione contro Salvini segnale preoccupante, disinformazione inaccettabile”
- Lido dei Pini, entro la prossima settimana il ripristino di cinque attraversamenti pedonali
- Manovra: Mattia (FDI), 19 Mld per Agricoltura e pesca, investimento mai visto
- AGGIORNAMENTO AGENDA MINISTRO MATTEO SALVINI
- ZES: Battistoni (FI), iniziativa per Paese più competitivo